Descriptor: "Nivolumab -- Reports" / Journal: globenewswire - Searchworks@Jio Institute Digital Library Search Results

Subjects: United States. Food and Drug Administration -- Reports -- International economic relations, bluebird bio, Inc. -- International economic relations, Bristol-Myers Squibb Co. -- International economic relations, Celgene Corp. -- International economic relations, Durvalumab -- Reports, Nivolumab -- Reports, Hyaluronidase -- Reports, Kinase inhibitors -- Reports, Biotechnology industries -- International economic relations -- Industry forecasts, Pembrolizumab -- Reports, Daratumumab -- Reports, Epidemiology -- Reports, Pharmaceutical industry -- International economic relations -- Industry forecasts, Antineoplastic agents -- Reports, Decitabine -- Reports, Banking, finance and accounting industries, Business, Darzalex (Medication) -- Reports
Abstract: Dublin, Sep 01, 2020 (GLOBE NEWSWIRE via COMTEX) -- The 'Multiple Myeloma - Market Insights, Epidemiology and Market Forecast - 2030' drug pipelines has been added to ResearchAndMarkets.com's offering. This [...]
Published: 2020

Subjects: United States. Food and Drug Administration -- Reports, Thyroid cancer -- Reports, Nivolumab -- Reports, Lenvatinib -- Reports, Antineoplastic agents -- Statistics -- Reports, Ipilimumab, Drugs, Trametinib, Thyroid diseases, Dabrafenib, Vandetanib, Cabozantinib, Banking, finance and accounting industries, Business
Abstract: Dublin, March 04, Mar 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- The 'Thyroid Cancer Drugs Global Market Report 2020' report has been added to ResearchAndMarkets.com's offering. The global thyroid cancer [...]
Published: 2020

Subjects: Cancer treatment -- Reports, Ipilimumab -- Reports, Cancer -- Reports, Atezolizumab -- Reports, Nivolumab -- Reports, Cancer research -- Reports, Pembrolizumab -- Reports, Emerging markets, Banking, finance and accounting industries, Business
Abstract: Pune, Feb 28, 2020 (GLOBE NEWSWIRE via COMTEX) -- Global 'Checkpoint Inhibitors for Treating Cancer' market report 2020 - 2025 offers a far-reaching analysis of key drivers, leading market players, [...]
Published: 2020

Subjects: Merck KGaA -- Forecasts and trends -- Reports, Bristol-Myers Squibb Co. -- Forecasts and trends -- Reports, Pfizer Inc. -- Forecasts and trends -- Reports, AstraZeneca PLC -- Forecasts and trends -- Reports, Brand names -- Reports, Durvalumab -- Reports, Ipilimumab -- Reports, Atezolizumab -- Reports, Nivolumab -- Reports, Stocks -- Reports, Avelumab -- Reports, Pembrolizumab -- Reports, Pharmaceutical industry -- Forecasts and trends -- Reports, Accounting, Cemiplimab, Backup software, Market trend/market analysis, Banking, finance and accounting industries, Business, Opdivo (Medication) -- Reports, Keytruda (Medication) -- Reports
Abstract: Dublin, Feb 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- The 'Immune Checkpoint Inhibitors Market' report has been added to ResearchAndMarkets.com's offering. Global immune checkpoint inhibitors market reached $22 billion in [...]
Published: 2020

Subjects: Vaccines -- Reports, Blinatumomab -- Reports, Bevacizumab -- Reports, Nivolumab -- Reports, Leukemia -- Reports, Pembrolizumab -- Reports, Pharmaceutical industry -- Industry forecasts -- Reports, Melanoma -- Reports, Lymphomas -- Reports, Non-small cell lung cancer -- Reports, Antineoplastic agents -- Reports, Brentuximab vedotin, Cancer vaccines, Cancer, Tumors, Biotechnology industries, Ipilimumab, Lung cancer, Banking, finance and accounting industries, Business
Abstract: Dublin, Feb 03, 2020 (GLOBE NEWSWIRE via COMTEX) -- The 'Immuno-Oncology Market, By Type (mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)), By Application (Lung, Melanoma, Leukemia, [...]
Published: 2020

Subjects: Atezolizumab -- Innovations -- Reports, Nivolumab -- Reports, Chemotherapy -- Reports, Small cell lung cancer -- Reports, Pembrolizumab -- Reports, Non-small cell lung cancer -- Reports, Banking, finance and accounting industries, Business
Abstract: Dublin, Oct 30, 2019 (GLOBE NEWSWIRE via COMTEX) -- The 'Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease' report [...]
Published: 2019

Subjects: Pfizer Inc. -- Growth -- Reports, Atezolizumab -- Reports, Bevacizumab -- Reports, Nivolumab -- Reports, Vascular endothelial growth factor -- Growth -- Reports, Avelumab -- Reports, Pembrolizumab -- Reports, Pharmaceutical industry -- Growth -- Reports, Cancer metastasis -- Development and progression -- Reports, Antineoplastic agents -- Reports, Carcinoma, Cancer, Endothelial growth factors, Phenols (Class of compounds), Renal cell carcinoma, Cabozantinib, Tumors, Ipilimumab, Tyrosine, Endothelium, Axitinib, Sunitinib, Company growth, Banking, finance and accounting industries, Business, Cabometyx (Medication) -- Reports
Abstract: Dublin, June 26, Jun 26, 2019 (GLOBE NEWSWIRE via COMTEX) -- The 'Cabometyx' report has been added to ResearchAndMarkets.com's offering. Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor [...]
Published: 2019

Searchworks